>> so this is a regulatory issue. and dr. mina has spoken about this and i certainly worked from inside the administration. there are regulatory standards here that approach these more as an individual test to make a diagnosis versus a public health measure. and i do agree that although the fda has done a great job, we do need to approve more very quickly. that's one reason at the end of the administration we allowed eua authority to be under me, as the assistant secretary, to rapidly approve these kinds of tests, to get them on the market. that was reversed, so i think we're back where we started at the early part of 2020. there needs to be regulatory reform and it needs to happen quickly. >> admiral giroir, thank you so much for being here. >> thank you. social media reaction already coming in to tonight's program. what do we have? we have a long one. that's what it is.